Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia

►Lomitapide was recently approved as an adjunct treatment for homozygous familial hypercholesterolemia.►The case of a patient with homozygous familial hypercholesterolemia treated with lomitapide for >5 years is presented.►Lipid-lowering response to lomitapide treatment has been significant.►Careful monitoring of diet, liver function, and concomitant medication was necessary.►The possibility of drug-drug interactions should be carefully assessed.

We report the case of a 49-year-old woman with homozygous familial hypercholesterolemia and a complicated cardiovascular history, treated for 5 years with a microsomal triglyceride transfer protein inhibitor in addition to her other lipid-lowering therapy.